Plavix

• Antiplatelet Agents
• Platelet Aggregation Inhibitors
• Fibrinolytic Agents
• ATC:B01AC04

• Clopidogrel sulfate
• Clopidogrel [Ban:Inn]
• Plavix

• No information avaliable

C₁₆H₁₆ClNO₂S

http://www.rxlist.com/cgi/generic/clopidog.htm

Plavix FDA

Plavix MSDS

D. Aubert et al.; U.S. Pat. 4,529,596(1985)

321.822 g/mol

158^oC

50.78 mg/L

solid

No information avaliable

Tablet (round, biconvex, film-coated)

For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease

Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to reduce atherosclerotic events such as myocardial infarction, stroke, and vascular death in patients who have had a recent stroke, recent MI, or have established peripheral vascular disease.

Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food.

Symptoms of acute toxicity include vomiting (in baboons), prostration, difficult breathing, and gastrointestinal hemorrhage.

Patients should be told that they may bleed more easily and it may take them longer than usual to stop bleeding when they take Plavix or Plavix combined with aspirin, and that they should report any unusual bleeding to their physician. Patients should inform physicians and dentists that they are taking Plavix and/or any other product known to affect bleeding before any surgery is scheduled and before any new drug is taken.

Humans and other mammals